J. M. Anto (Barcelona, Spain), P. Vermeire (Antwerp, Belgium)
Symptoms preceding development of COPD - a 10-year perspective
A. C. Jonsson, A. Lindberg, L. G. Larsson, E. Rönmark, B. Lundbäck (Luleå, Stockholm, Sweden)
|  |
10-year cumulative incidence of COPD in a symptomatic cohort using BTS and GOLD spirometric criteria
A. Lindberg, L. G. Larsson, A. C. Jonsson, B. Lundbäck (Luleå, Stockholm, Sweden)
| |
Prevalence of chronic symptoms and bronchial obstruction according to the GOLD classification in the young adult general population
R. de Marco, S. Accordini, I. Cerveri, A. Corsico, J. Sunyer, F. Neukirch, N. Kuenzli, B. Leynaert, T. Gislason, P. Vermeire, C. Svanes, J. M. Anto, P. Burney (Verona, Italy)
| |
Pre- and post- bronchodilator FEV1 does not perturb a multidimensional system (IDS) for categorising the clinical impact of COPD: comparison of ERS, BTS and GOLD guidelines
A. Lawrence, I. K. Taylor, N. P. Keaney (Sunderland, United Kingdom)
| |
Individual quality of life in COPD patients - a SEIQoL analysis
A. J. Tynan, S. J. Lane (Dublin, Ireland)
| |
Correlation between the quality of life questionnaires and pulmonary lung functions in COPD patients
Z. Gulbaran, G. Izmirogullari, P. Cagatay, T. Cagatay (Istanbul, Turkey)
| |
Influence of early withdrawal on estimates of health status decline
S. Spencer, S. Gavriel, P. W. Jones (London, United Kingdom)
| |
Modelling the impact of differential dropout on estimated rates of health status decline
S. Gavriel, S. Spencer, P. W. Jones (London, United Kingdom)
| |
Mannan-binding lectin deficiency as a risk factor for asthma and COPD. The Copenhagen city heart study
M. Dahl, A. Tybjaerg-Hansen, P. Lange, J. Vestbo, B. G. Nordestgaard (Copenhagen, Denmark)
| |
Psychiatric disturbances and COPD in an Italian primary care population
S. Baldacci, M. Borbotti, F. Di Pede, A. Angino, F. Martini, B. Piegaia, G. Viegi (Pisa, Italy)
| |
Gender differences in COPD treatment and morbidity in patients from the confronting COPD international survey
| |
The cost of COPD in the emergency department and hospital
R. Stanford, C. Roberts (Raleigh, Yardley, United States Of America)
| |
Economic outcomes in the United States of treating COPD with inhaled corticosteroids and long-acting β-agonists in a managed care setting
Y. M. Gagnon, D. W. Maple, A. R. Levy, J. S. Hurley, F. J. Frost, M. D. Spencer, A. H. Briggs (Vancouver, Canada; Albuquerque, United States Of America; London, Oxford, United Kingdom)
| |
The main disease-related cost drivers in COPD: impaired lung function and exacerbations
S. A. Jansson, A. Ericsson, A. Lindberg, S. Borg, A. C. Jonsson, E. Rönmark, F. Andersson, B. Lundbäck (Luleå, Umeå, Lund, Stockholm, Sweden)
| |
Direct costs of COPD in a population attending a hospital clinic
A. J. Tynan, S. M. Lane (Dublin, Ireland)
| |
Health services utilisation by COPD patients in clinical stability and during an exacerbation
J. Garcia-Aymerich, J. Escarrabill, J. M. Antó (Barcelona, Spain)
| |
Trends in COPD-related hospitalisations in Sweden
F. L. Andersson, M. de Verdier, K. Svensson (Lund, Sweden)
| |
Influence of age, gender and respiratory function inpairment on acceptability for culture of sputum samples in microbiological study during acute exacerbation of chronic bronchitis
M. Biagini, M. Naldi, M. Rossi (Arezzo, Siena, Italy)
| |
The course of disease of patients who died from asthma and COPD
K. L. May (Warsaw, Poland)
| |
Financial impact of COPD on long-term disability pension programs
R. Nordyke, S. Isonaka, K. DesFosses, C. Justus (Santa Monica, United States Of America; Ingelheim, Germany)
| |